MX2013003168A - Anticuerpo contra ephrin b2 y su uso. - Google Patents
Anticuerpo contra ephrin b2 y su uso.Info
- Publication number
- MX2013003168A MX2013003168A MX2013003168A MX2013003168A MX2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A
- Authority
- MX
- Mexico
- Prior art keywords
- ephrin
- antibody
- lymphangiogenesis
- cancer
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201031402A ES2378976B1 (es) | 2010-09-21 | 2010-09-21 | Anticuerpo contra ephrin b2 y su uso. |
| PCT/ES2011/070655 WO2012038573A1 (es) | 2010-09-21 | 2011-09-20 | Anticuerpo contra ephrin b2 y su uso |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013003168A true MX2013003168A (es) | 2013-08-21 |
Family
ID=45873482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003168A MX2013003168A (es) | 2010-09-21 | 2011-09-20 | Anticuerpo contra ephrin b2 y su uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9062109B2 (enExample) |
| EP (1) | EP2620449A4 (enExample) |
| JP (1) | JP2013542720A (enExample) |
| KR (1) | KR20140014062A (enExample) |
| CN (1) | CN103237812A (enExample) |
| AU (1) | AU2011306816A1 (enExample) |
| BR (1) | BR112013005977A2 (enExample) |
| CA (1) | CA2812727A1 (enExample) |
| ES (1) | ES2378976B1 (enExample) |
| MX (1) | MX2013003168A (enExample) |
| RU (1) | RU2013118454A (enExample) |
| WO (1) | WO2012038573A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104694477B (zh) * | 2015-03-03 | 2018-04-17 | 西安交通大学 | 一种EphrinB2高表达的重组HEK293细胞及其应用 |
| JP2022516611A (ja) * | 2018-12-28 | 2022-03-01 | ザ ジェネラル ホスピタル コーポレイション | 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体 |
| US20220213214A1 (en) * | 2019-05-14 | 2022-07-07 | Sanford Health | Anti-human ephrin B1 antibodies and uses thereof |
| WO2020242910A1 (en) * | 2019-05-24 | 2020-12-03 | The Regents Of The University Ofcalifornia | Compositions and methods for treating cancer |
| TW202547871A (zh) * | 2024-03-27 | 2025-12-16 | 美商麥第爾醫療公司 | 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法 |
| CN121159668A (zh) * | 2025-09-12 | 2025-12-19 | 北京威斯克生物医药有限公司 | Ephrin-B2重组蛋白及其疫苗、制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004260884B2 (en) * | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| JP2007320850A (ja) * | 2004-08-24 | 2007-12-13 | Kyowa Hakko Kogyo Co Ltd | 抗エフリンｂ２抗体 |
| EP1954720A1 (en) * | 2005-10-31 | 2008-08-13 | The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health | Antibodies and immunotoxins that target human glycoprotein nmb |
| RU2451031C2 (ru) * | 2006-01-20 | 2012-05-20 | Дженентек, Инк. | Антитела к эфрину в2 и способы их применения |
| PL1972637T3 (pl) * | 2007-03-19 | 2012-01-31 | Univ Stuttgart | Antagoniści selektywni wobec huTNFR1 |
| WO2010019565A2 (en) * | 2008-08-12 | 2010-02-18 | Medlmmune, Llc | Anti-ephrin b2 antibodies and their use in treatment of disease |
-
2010
- 2010-09-21 ES ES201031402A patent/ES2378976B1/es not_active Expired - Fee Related
-
2011
- 2011-09-20 KR KR1020137007045A patent/KR20140014062A/ko not_active Withdrawn
- 2011-09-20 US US13/824,171 patent/US9062109B2/en not_active Expired - Fee Related
- 2011-09-20 CN CN2011800534643A patent/CN103237812A/zh active Pending
- 2011-09-20 MX MX2013003168A patent/MX2013003168A/es not_active Application Discontinuation
- 2011-09-20 RU RU2013118454/10A patent/RU2013118454A/ru not_active Application Discontinuation
- 2011-09-20 JP JP2013528731A patent/JP2013542720A/ja active Pending
- 2011-09-20 CA CA2812727A patent/CA2812727A1/en not_active Abandoned
- 2011-09-20 EP EP11826446.4A patent/EP2620449A4/en not_active Withdrawn
- 2011-09-20 BR BR112013005977A patent/BR112013005977A2/pt not_active IP Right Cessation
- 2011-09-20 AU AU2011306816A patent/AU2011306816A1/en not_active Withdrawn
- 2011-09-20 WO PCT/ES2011/070655 patent/WO2012038573A1/es not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN103237812A (zh) | 2013-08-07 |
| WO2012038573A1 (es) | 2012-03-29 |
| CA2812727A1 (en) | 2012-03-29 |
| KR20140014062A (ko) | 2014-02-05 |
| US9062109B2 (en) | 2015-06-23 |
| US20130287795A1 (en) | 2013-10-31 |
| EP2620449A1 (en) | 2013-07-31 |
| ES2378976B1 (es) | 2013-05-06 |
| RU2013118454A (ru) | 2014-10-27 |
| EP2620449A4 (en) | 2014-03-26 |
| JP2013542720A (ja) | 2013-11-28 |
| BR112013005977A2 (pt) | 2019-09-24 |
| AU2011306816A1 (en) | 2013-04-04 |
| ES2378976A1 (es) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630542A (en) | Methods of treating a tauopathy | |
| PH12014501039B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| PH12015500390B1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| MX366130B (es) | Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos. | |
| GB201118656D0 (en) | New compounds | |
| MX349004B (es) | Nuevos compuestos. | |
| SG10201903119QA (en) | Polypeptide vaccine | |
| GB201209613D0 (en) | New compounds | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| WO2013114367A8 (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
| IL235672A0 (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| SG10201609772PA (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| MX366899B (es) | Nuevos compuestos. | |
| IN2015KN00657A (enExample) | ||
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| PL2852408T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| WO2014147503A3 (en) | Anti-bag3 antibodies for therapeutic use | |
| WO2013053034A3 (pt) | Tiazacridinas utilizadas na terapia anticâncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |